Day One (13th May 2025)Tuesday, 13 May 2025 - CET/CEST (Cent Europe Summer, GMT+2)

For decades, affinity purification platforms like Protein A and Protein L have been essential in the manufacturing of therapeutic monoclonal antibodies. However, the emergence of engineered modalities such as bispecific antibodies, fragments, and Fc-fusion proteins presents new challenges in downstream processing. To overcome these obstacles, affinity chromatography resins targeting specific antibody subdomains offer a promising solution for purifying these novel formats. This advancement is critical for enhancing the commercial manufacturing of next-generation antibody therapeutics.

This presentation will demonstrate how the Thermo Fisher CaptureSelect portfolio can be utilized as a versatile toolbox for the affinity purification of highly engineered antibody molecules, supported by real industry case studies.